Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects 18 to 65 years of age.~* Body Mass Index (BMI) ≤ 33 kg/m2, and total body weight of 60 kg to 90 kg (132 lbs to 198 lbs).~* Fasting LDL-C must be \> 130 mg/dL (borderline high per NCEP ATP III criteria) at two qualifying visits: initial screening (Days -28 to -14) and Day -7.~Exclusion Criteria:~* Poorly controlled type 1 or type 2 diabetes mellitus (HbA1c \> 9.0%).~* History of a cardiovascular or cerebrovascular event (eg, MI, stroke, TIA) or related procedure (eg, angioplasty) during the past year.~* Subjects who meet the New York Heart Association (NYHA) criteria for congestive heart failure (CHF) classes III or IV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single 150 mg PF-04950615 dose administered to the abdomen (Type: ACTIVE_COMPARATOR): None
- Single 150 mg PF-04950615 dose administered to the upper arm (Type: EXPERIMENTAL): None
- Single 150 mg PF-04950615 dose administered to the thigh (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).